Literature DB >> 24676754

11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT.

Chi-lai Ho1, Sirong Chen, Yim Lung Leung, Thomas Cheng, Ka-nin Wong, Shing Kee Cheung, Raymond Liang, Chor Sang Chim.   

Abstract

UNLABELLED: We prospectively compared (11)C-acetate with (18)F-FDG in a PET/CT evaluation of multiple myeloma (MM), specifically on diagnostic accuracy, identification of high-risk patients, and monitoring of treatment response.
METHODS: Dual-tracer PET/CT was performed on 35 pathologically and clinically confirmed and untreated patients (26 with symptomatic MM, 5 with smoldering MM, and 4 with monoclonal gammopathy of unknown significance) and 20 individuals with normal marrow.
RESULTS: (11)C-acetate showed significant incremental value over (18)F-FDG (84.6% vs. 57.7%) for positively identifying patients with diffuse and focal symptomatic MM, and was negative in patients with indolent smoldering MM and monoclonal gammopathy of unknown significance. Three functional parameters-number of (11)C-acetate-avid and (18)F-FDG-avid focal bone lesions and (11)C-acetate general marrow activity-strongly correlated with β-2-microglobulin as surrogate imaging markers of tumor burden. After induction chemotherapy, the metabolic change in (11)C-acetate general marrow activity correlated with clinical response.
CONCLUSION: Metabolic characterization of MM in diagnosis, risk stratification, and treatment monitoring can be done more accurately by assessing lipid metabolism with (11)C-acetate than by assessing glucose metabolism with (18)F-FDG.

Entities:  

Keywords:  11C-acetate; beta-2-microglobulin; myeloma

Mesh:

Substances:

Year:  2014        PMID: 24676754     DOI: 10.2967/jnumed.113.131169

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

1.  Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma.

Authors:  Francesca Fontana; Xia Ge; Xinming Su; Deep Hathi; Jingyu Xiang; Simone Cenci; Roberto Civitelli; Kooresh I Shoghi; Walter J Akers; Andre D'avignon; Katherine N Weilbaecher; Monica Shokeen
Journal:  Clin Cancer Res       Date:  2016-08-02       Impact factor: 12.531

2.  Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation.

Authors:  Daria Ripani; Carmelo Caldarella; Tommaso Za; Daniele Antonio Pizzuto; Elena Rossi; Valerio De Stefano; Alessandro Giordano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-27       Impact factor: 9.236

3.  18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.

Authors:  Thibaut Cassou-Mounat; Sona Balogova; Valérie Nataf; Marie Calzada; Virginie Huchet; Khaldoun Kerrou; Jean-Yves Devaux; Mohamad Mohty; Jean-Noël Talbot; Laurent Garderet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-28       Impact factor: 9.236

Review 4.  Attacking the supply wagons to starve cancer cells to death.

Authors:  Elizabeth M Selwan; Brendan T Finicle; Seong M Kim; Aimee L Edinger
Journal:  FEBS Lett       Date:  2016-03-22       Impact factor: 4.124

Review 5.  [Hemato-oncological imaging : Importance of hybrid procedures].

Authors:  M E Mayerhoefer; A Haug
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

Review 6.  New Approaches to Molecular Imaging of Multiple Myeloma.

Authors:  Ravi Vij; Kathryn J Fowler; Monica Shokeen
Journal:  J Nucl Med       Date:  2015-11-05       Impact factor: 10.057

7.  New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma.

Authors:  Charles Mesguich; Paolo Zanotti-Fregonara; Elif Hindié
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

8.  [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [18F]FDG and laboratory values.

Authors:  Constantin Lapa; Martin Schreder; Andreas Schirbel; Samuel Samnick; Klaus Martin Kortüm; Ken Herrmann; Saskia Kropf; Herrmann Einsele; Andreas K Buck; Hans-Jürgen Wester; Stefan Knop; Katharina Lückerath
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

Review 9.  The metabolic fate of acetate in cancer.

Authors:  Zachary T Schug; Johan Vande Voorde; Eyal Gottlieb
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

10.  In-house development of an optimized synthetic module for routine [11C]acetate production.

Authors:  Hwa Youn Jang; Seong Young Kwon; Ayoung Pyo; Min Goo Hur; Sang Wook Kim; Jeong-Hoon Park; Hee-Jung Kim; Seung Dae Yang; Sunwoo Lee; Dong-Yeon Kim; Jung-Joon Min
Journal:  Nucl Med Commun       Date:  2015-01       Impact factor: 1.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.